The information in this section is intended for visitors outside the United States.
What We Fund
For many years, Gilead has worked with local partners to provide our medicines throughout Latin America and the Caribbean. Gilead therapies continue to address unmet medical needs in the region, bringing innovative and life-saving treatments to communities in Argentina, Belize, Brazil, Haiti, Jamaica and elsewhere. The efforts of our corporate contributions team build upon Gilead’s overall mission, as we identify and support organizations that seek to:
In Latin America and the Caribbean, funding priority is given to projects within Gilead’s therapeutic areas of HIV and liver diseases.
Gilead places a strong emphasis on combating the HIV epidemic in the Latin America and Caribbean regions. Despite advancements in medicines and treatments, HIV’s devastating and inequitable impact remains, particularly among indigenous people living in remote regions of Peru as well as young people throughout Latin America. In the Caribbean, more than 230,000 people are living with the disease, making the region’s HIV prevalence the second highest of anywhere in the world. In other populous areas, the social stigma of HIV-positive status leads many to decline treatment or travel great distances to be treated outside their community. Elsewhere, poor treatment options for incarcerated populations (a group that faces systemic barriers to receiving quality HIV care) leads to public health concerns as individuals complete their rehabilitation programs and re-enter society.
Gilead supports organizations working to help individuals learn their status and get the care they need. We also fund groups looking to meet the unique needs of the region, including:
To support HIV education in the Caribbean, Gilead provides funding to Health[e]Foundation, a public benefit organization that trains health professionals in Jamaica on the epidemiology of HIV/AIDS using clinical case studies. Gilead helps Health[e]Foundation deliver its education courses throughout the country’s cities and rural areas. After completing the training, local healthcare workers have demonstrated enhanced clinical and evidence-based knowledge, enabling improved capacity for treating HIV.
Treating hepatitis B (HBV), hepatitis C (HCV) and other forms of liver disease can be a challenge in Latin America and the Caribbean for a variety of reasons. One critical difficulty centers on reaching at-risk groups with screening and diagnosis. The estimated percentage of undiagnosed individuals living with HCV in Latin America and the Caribbean has gone unchanged over the span of many years. Lack of disease awareness and diagnosis options have contributed to the persistence of this gap. Even in areas where intravenous drug use and other risky behaviors are better understood, many hospital procedures are not performed in sterile conditions, with individuals contracting viral hepatitis in the process.
Gilead’s grantee partners seek to increase awareness of risk factors and the educational tools available to patient communities throughout the region. Gilead also funds projects to improve diagnostics and build medical specialization in HBV and HCV.
Gilead is working to improve the overall continuum of care for liver diseases by funding organizations that:
Gilead supports GADA — a group that promotes humans rights for populations vulnerable to viral hepatitis and other diseases — on its HCV diagnosis activities across São Paulo, Brazil. GADA promotes education and raises awareness of HCV diagnosis in men and women over 45 who are particularly at risk because of participation in activities such as tattooing, nail care, endoscopy, dentistry and hemodialysis services. Through a program that Gilead helped fund in 2015, GADA reached more than 1.5 million people. A pre- and post-evaluation of the program showed that early diagnosis in the region more than doubled over its two-year duration.
Though priority is given to HIV- and liver disease-related projects, Gilead will consider grant proposals in areas outside of these therapeutic areas, provided they conform to Gilead’s eligibility restrictions. These proposals may include (but are not limited to):